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801Abstracts
OBJECTIVES: To estimate the cost-consequences of treating
women for Stress Urinary Incontinence (SUI) with a pharma-
ceutical intervention—Duloxetine—from the perspective of the
statutory health insurance in Germany. METHODS: A decision-
tree was developed by a panel of clinical experts to model bi-
annual cost-consequences of three treatment strategies: 1) initial
Duloxetine treatment, followed either by continuation of Dulox-
etine, no further treatment or surgical intervention(s); 2) initial
placebo treatment (physician visits), then no further treatment
or surgical intervention(s); and 3) Standard treatment including
surgical intervention(s). Pelvic Floor Exercises were considered
in all arms. Model input for the ﬁrst three months were taken
from one phase 2 and three phase 3 placebo-controlled studies
assessing the efﬁcacy and safety of Duloxetine. 950 patients with
moderate to severe SUI (Incontinence Episodes Frequency, IEF
>= 14/week) were included in the analysis. Success of treatment
was classiﬁed as “full response” (100% reduction in IEF) and
“successful treatment but not dry” (50.0%–99.9% reduction in
IEF). The likelihood of continuation of Duloxetine beyond three
months was based on the patient’s perception of improvement
as assessed by a validated questionnaire. Success rates for the
considered surgical procedures were drawn from the literature
and expert opinion. Diagnosis Related Groups (2004) for
surgery and the Einheitliche Bewertunsmaßstab (EBM) (2003)
for outpatient resource use were taken to derive costs. Placebo
will not present an option in routine practice, but is presented
because of the clinical trial design. RESULTS: Expected bi-
annual costs per women are: Duloxetine treatment 2205€;
placebo treatment 2034€, and 2092€ for standard treatment.
Duloxetine generates a higher probability of avoiding surgery
(36%), compared with placebo (24%) and standard treatment
(20%). CONCLUSIONS: Treating SUI in women with Duloxe-
tine leads to comparable costs to standard treatment. Model lim-
itations include extrapolation of clinical trial data and parameter
input by clinical experts.
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LONG-TERM COST-EFFECTIVENESS MODELLING OF
FEEDBACK MICROWAVE THERMOTHERAPY VERSUS DRUG
TREATMENT IN PATIENTS WITH BENIGN PROSTATIC
HYPERPLASIA AND LOWER URINARY TRACT SYMPTOMS
Hjelmgren J1, Malmberg L2, Ragnarson-Tennvall G1
1The Swedish Institute for Health Economics (IHE), Lund, Sweden;
2Lund University Hospital, Lund, Sweden
OBJECTIVES: The purpose was to develop an economic model
for simulation of the long-term cost-effectiveness of treatment
with ProstaLund Feedback Treatment (PLFT) versus alpha-
blockade in patients with benign prostatic hyperplasia (BPH) 
and lower urinary tract symptoms (LUTS). The model was
applied using information about Swedish treatment practice.
METHODS: Data from published literature, treatment pro-
grams, and ofﬁcial Swedish price lists was used to develop a
disease progression model for patients with BPH and LUTS
according to the International Prostate Symptom Score (IPSS).
Three important time dependent features of disease progression
were regarded in the model: 1) a phase where initial symptoms
are reduced; 2) a stationary post-treatment phase; and 3) a phase
where the probability of a re-intervention will increase. All the
three phases could be adjusted in the model to capture differ-
ences in treatment effects between different treatment options.
Costs and quality adjusted life years (QALY) were calculated for
a period of three years and discounted at 3%. The calculations
were made in Euro (2003 prices). A sensitivity analysis was per-
formed where scenarios regarding baseline disease severity, treat-
ment effects, time horizon, discount rate, age at initiation of
treatment, QALY weights, and assumption about the probabil-
ity of re-treatment were altered. RESULTS: The total three-year
cost of PLFT (including re-treatment) and alfa-blockade was esti-
mated to 2059€ and 1411€, respectively. According to the model
PLFT would result in 0.07–0.10 more QALYs compared to alfa-
blockade resulting in a cost-effectiveness ratio of €6600–9500.
Due to lower future expected costs of PLFT compared to alfa-
blockade the results indicate that PLFT would be cost-saving if
the time perspective is extended to ﬁve years. CONCLUSIONS:
According to the assumptions made in the model, PLFT is cost-
effective compared to alpha-blockade. The main conclusion
remained stable in the sensitivity analysis.
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OBJECTIVES: To prospectively evaluate the survival of patients
<65 years who initiated hemodialysis (HD) in our region and to
investigate factors associated with survival. METHODS: All
patients < 65 years who started HD in our region between
January, 2001 and September, 2002 and who remained in renal
replacement therapy (RRT) at least 3 months were included and
followed-up to March, 2004 (N = 78). Patients with severe cog-
nitive deterioration were excluded (n = 1). The health related
quality of life (HRQoL) was evaluated using the SF-36 Health
Survey (Physical-PCS and Mental-MCS Component Summary
Scores) and the Kidney Disease Questionnaire (Physical
Symptom scale-PSS) at 3 months from start and at 1 and 2 years
later. Sociodemographic and clinical data, the Karnofsky Scale
score and a comorbidity index were also collected. SF-36 scores
were standardized using the Spanish general population norms.
Kaplan-Meier survival curves and Cox Proportional hazard
regression model were used for the survival analysis. In order to
adjust the effect of age on mortality the Relative Risk of Mor-
tality (RRM) was calculated using the population rates.
RESULTS: At the end, the 2-year survival rate was 88.3%, but
the RRM fell progressively from 30 in the younger patients
(34–43 years) to 6.33 in the older ones (55–64 years). Kaplan-
Meier analysis showed that those with MCS lower than 40 at 3
months from start and those who had not received a kidney
transplant at the second year of the follow-up had lower survival
(p = 0.0074 and 0.0008 respectively). Cox Proportional hazard
regression model with both variables showed that patients with
MCS lower than 40 had higher mortality risk: hazard ratio =
6.94 (95%CI = 1.34–35.99) p = 0.021. CONCLUSIONS:
Patients between 34 and 43 years showed higher RRM. The
mental aspects of the HRQoL could have an important role in
the survival of patients on RRT under 65 years.
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OBJETIVES: There is already some degree of evidence about the
greater capacity of adaptation to RRT of elderly patients vs. the
